Two patients at the DENT Neurologic Institute near Buffalo, N.Y., will be the first in the nation to receive the newest drug to treat ALS in more than 2 decades. Radicava, is designed to help control excessive oxidative stress in the body, which occurs at a higher rate in ALS patients. Radicava is administered by a healthcare provider via intravenous infusion with the initial treatment cycle of daily dosing for 14 days, followed by a 14-day drug-free period.